8-K: Mirum Completes Bluejay Acquisition, Boosts Rare Disease Portfolio

Mirum Pharmaceuticals has completed its acquisition of Bluejay Therapeutics, adding brelovitug for chronic hepatitis delta virus to its rare disease pipeline and securing $268.5 million in private placement financing.

Summary

• Mirum Pharmaceuticals completed the acquisition of Bluejay Therapeutics on January 23, 2026, through a previously announced merger agreement.
• The acquisition includes worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), a severe rare liver disease with no FDA-approved therapies in the United States.
• Brelovitug has received FDA Breakthrough Therapy and European Medicines Agency (EMA) PRIME designations and is currently being evaluated in the global AZURE Phase 3 registrational program.
• Topline data from the AZURE Phase 3 program is expected in the second half of 2026, with a potential Biologics License Application (BLA) submission and launch in 2027.
• Mirum acquired Bluejay for an upfront consideration of $280.8 million in cash and 4,673,597 shares of Mirum common stock, plus a holdback of $25.8 million in cash and 522,375 shares of common stock.
• Additional milestone payments of up to $200 million in cash are contingent on achieving certain net sales milestones.
• Concurrently with the acquisition, Mirum closed private placement financings, raising aggregate gross proceeds of approximately $268.5 million from existing and new healthcare investors.
• As of January 23, 2026, immediately following the acquisition and private placements, 59,879,958 shares of Mirum's common stock are issued and outstanding.

Sentiment

Score: 8

Explanation: The acquisition of a late-stage asset addressing a significant unmet medical need, coupled with successful capital raising to fund its development, represents a strong strategic move for Mirum. The positive Phase 2 data for brelovitug and its Breakthrough Therapy designation further enhance the positive outlook, despite the associated costs and dilution.

Positives

• The acquisition significantly expands Mirum's global leadership in rare disease, particularly in rare liver conditions, by adding a late-stage asset.
• Brelovitug addresses a critical unmet medical need for chronic HDV, a severe liver disease with no FDA-approved treatments in the U.S., affecting approximately 230,000 people in the U.S. and Europe.
• Brelovitug has received FDA Breakthrough Therapy and EMA PRIME designations, indicating its potential to provide significant therapeutic advantage.
• Phase 2 studies demonstrated strong antiviral activity for brelovitug, achieving a 100% HDV RNA response, improvements in liver enzyme levels, and a favorable safety profile.
• The concurrent private placement raised approximately $268.5 million, providing substantial capital to support the clinical development and commercialization of brelovitug.
• The program is expected to benefit from Mirum's deep expertise in rare liver conditions and existing global development and commercial synergies.

Negatives

• The acquisition involves a substantial cash outlay of $306.6 million (upfront and holdback), plus potential future milestone payments of up to $200 million.
• The issuance of 5,195,972 shares of Mirum common stock for the acquisition will result in shareholder dilution.
• There are inherent integration risks associated with combining Bluejay's team and assets into Mirum's existing business operations.
• Required financial statements and pro forma financial information for the acquired business are not immediately available and will be filed by amendment at a later date.

Risks

• Risks associated with the development of acquired product candidates, including the failure of any expected synergies to be realized.
• Risks and uncertainties arising from the integration of an acquired company, its employees, and its assets with Mirum's business.
• The perceived benefits of the acquisition may not be fully realized.
• Risks and uncertainties with the development of investigational medicines generally, including the failure of future studies to generate the same or similar data as prior studies.
• The potential that estimated prevalences of HDV in the United States and Europe are materially inaccurate.
• General business risks, the impact of geopolitical and macroeconomic events.

Future Outlook

Mirum Pharmaceuticals anticipates a strong focus on execution, including integrating the Bluejay team and assets, completing the global AZURE Phase 3 program for brelovitug, and preparing for potential regulatory registrations and commercial launches. Topline data from the Phase 3 studies for brelovitug are expected in the second half of 2026, with a potential BLA submission and launch in 2027. The company also plans to evaluate strategic options for Bluejay's additional investigational programs, and the proceeds from the private placements are intended to support brelovitug's clinical development and commercial activities.

Management Comments

• "With the acquisition now complete, our focus shifts to execution – adding the talented Bluejay team to Mirum as we complete the AZURE Phase 3 program and prepare for potential registrations and launches."
• "This program fits squarely within our core strengths in rare disease and builds on our deep expertise in rare liver conditions."
• "We believe Mirum’s global development and commercial synergies position us well to deliver for patients living with HDV."

Industry Context

This acquisition strategically enhances Mirum Pharmaceuticals' position within the rare disease market, particularly in severe liver conditions. The addition of brelovitug, a late-stage asset for chronic HDV, addresses a critical unmet medical need, as there are currently no FDA-approved therapies for HDV in the United States. This move aligns with a broader industry trend of pharmaceutical companies acquiring specialized biotechnology firms to expand their pipelines with innovative therapies for rare diseases, which often command premium pricing and face less competition. The focus on HDV, a severe form of viral hepatitis affecting a significant patient population in the US and Europe, underscores the strategic value of this acquisition within the rare liver disease segment.

Comparison to Industry Standards

• NA

Related Party Transactions

• Entities affiliated with Frazier Life Sciences IX, L.P., which are associated with a member of Mirum's board of directors and are beneficial owners of more than five percent of Mirum's outstanding capital stock, were Target security holders and received their pro rata portion of the Upfront Consideration and are entitled to receive their pro rata portion of the remainder of the Merger Consideration.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through portfolio expansion and addressing a high-value unmet medical need, balanced by immediate dilution from stock issuance and significant cash outlay.
• Patients (with HDV): Significant positive impact as brelovitug represents a promising late-stage therapy for a severe disease with no approved treatments.
• Employees (Bluejay): Integration into Mirum, potentially offering new opportunities within a larger rare disease company.
• Creditors: The private placement provides capital, potentially strengthening Mirum's financial position to manage the acquisition costs.

Next Steps

• Integration of the Bluejay Therapeutics team and assets into Mirum Pharmaceuticals.
• Completion of the global AZURE Phase 3 clinical program for brelovitug.
• Preparation for potential regulatory registrations and commercial launches of brelovitug.
• Evaluation of strategic options for Bluejay's additional investigational programs.
• Filing of required financial statements and pro forma financial information by amendment to the Form 8-K no later than April 10, 2026.
• Anticipated topline Phase 3 results for brelovitug in the second half of 2026.
• Potential BLA submission and launch of brelovitug in 2027.

Key Dates

Recommendation

The acquisition of Bluejay Therapeutics, particularly the late-stage asset brelovitug with its Breakthrough Therapy designation and strong Phase 2 data, significantly enhances Mirum's pipeline and market position in rare liver diseases. The concurrent private placement provides substantial capital to fund the development and commercialization of this high-potential asset, mitigating immediate financial strain. Given the severe unmet medical need for HDV and brelovitug's promising profile, this strategic move is expected to drive substantial long-term value, making it a compelling investment opportunity.

Keywords

Mirum Pharmaceuticals, Bluejay Therapeutics, acquisition, merger, rare disease, hepatitis delta virus, HDV, brelovitug, AZURE, Phase 3, clinical trial, biotechnology, liver disease, Breakthrough Therapy, PRIME designation, private placement, capital raise, M&A